Publications

Detailed Information

Cost of treatment for multidrug-resistant tuberculosis in South Korea

DC Field Value Language
dc.contributor.authorKang, Young Ae-
dc.contributor.authorChoi, Yong-Jun-
dc.contributor.authorCho, Young-Jae-
dc.contributor.authorLee, Sang Min-
dc.contributor.authorYoo, Chul-Gyu-
dc.contributor.authorKim, Young Whan-
dc.contributor.authorHan, Sung Koo-
dc.contributor.authorShim, Young-Soo-
dc.contributor.authorYim, Jae-Joon-
dc.date.accessioned2010-01-07T01:33:18Z-
dc.date.available2010-01-07T01:33:18Z-
dc.date.issued2006-10-21-
dc.identifier.citationRespirology. 2006 Nov;11(6):793-8.en
dc.identifier.issn1323-7799 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17052310-
dc.identifier.urihttps://hdl.handle.net/10371/27661-
dc.description.abstractOBJECTIVE AND BACKGROUND: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. METHODS: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. RESULTS: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17,457 (US$10,133-26,418) in the surgically treated group and US$33,362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15,856 (US$10,752-38,421), US$47,159 (US$20,587-77,622) and US$478,357 (US$257,377-777,778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). CONCLUSIONS: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.en
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.subjectAdulten
dc.subjectEfficiency, Organizational/economicsen
dc.subjectFemaleen
dc.subjectHealth Care Costs/*statistics & numerical dataen
dc.subjectHumansen
dc.subjectKorea/epidemiologyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrevalenceen
dc.subjectTime Factorsen
dc.subjectTuberculosis, Multidrug-Resistant/*drug therapy/*economics/epidemiologyen
dc.subjectTuberculosis, Pulmonary/*drug therapy/*economics/epidemiologyen
dc.titleCost of treatment for multidrug-resistant tuberculosis in South Koreaen
dc.typeArticleen
dc.contributor.AlternativeAuthor강영애-
dc.contributor.AlternativeAuthor최용준-
dc.contributor.AlternativeAuthor조영재-
dc.contributor.AlternativeAuthor이상민-
dc.contributor.AlternativeAuthor유철규-
dc.contributor.AlternativeAuthor김영환-
dc.contributor.AlternativeAuthor한성구-
dc.contributor.AlternativeAuthor심영수-
dc.contributor.AlternativeAuthor임재준-
dc.identifier.doi10.1111/j.1440-1843.2006.00948.x-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share